PMID- 36415442
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221124
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 10
DP  - 2022 Oct
TI  - Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Infertility 
      Due to Premature Ovarian Failure.
PG  - e30529
LID - 10.7759/cureus.30529 [doi]
LID - e30529
AB  - Females belonging to the reproductive age group may face challenges regarding 
      infertility or miscarriage due to conditions such as premature ovarian failure 
      (POF). It is the condition that happens when a female's ovaries stop working 
      before she is 40. The majority of the causes of POF cases are idiopathic. Other 
      reasons include genetic disorders (Turner's syndrome, bone morphogenetic protein 
      15 (BMP15) mutation, galactosemia, mutation of forkhead box protein L2 (FOXL2), 
      growth differentiation factor-9 (GDF9), mutation of luteinizing hormone (LH) and 
      follicle-stimulating hormone receptors (FSHR), etc.), enzymatic mutation such as 
      aromatase, autoimmune disorders (Addison's disease, vitiligo, systemic lupus 
      erythematosus, myasthenia gravis, autoimmune thyroiditis, autoimmune 
      polyglandular syndrome, etc.), vaccination, and environmental factors (cigarette 
      smoking, toxins, and infections). Many attempts have been made to treat POF by 
      various methods. Some of the methods of treatment include hormone replacement 
      therapy (HRT), melatonin therapy, dehydroepiandrosterone (DHEA) therapy, and stem 
      cell therapy. Stem cell therapy has proven to be the most efficient form for 
      treating POF as compared to all other options. Umbilical cord-derived mesenchymal 
      stem cells (UC-MSCs) are the best among the other sources of mesenchymal stem 
      cells (MSCs) for the treatment of POF as they have a painless extraction 
      procedure. They have a tremendous capacity for self-repair and regeneration, 
      which helps them in restoring degenerated ovaries. This review includes 
      information on the causes of POF, its efficacious therapeutic approaches, and the 
      impact of transplantation of human umbilical cord mesenchymal stem cells 
      (hUCMSCs) as an option for the therapy of POF. Numerous studies conducted on stem 
      cell therapy prove that it is an effective approach for the treatment of 
      sterility.
CI  - Copyright (c) 2022, Garg et al.
FAU - Garg, Kritika
AU  - Garg K
AD  - Department of Pharmacology, Jawaharlal Nehru Medical College, Datta Meghe 
      Institute of Medical Sciences, Wardha, IND.
FAU - Zilate, Sarju
AU  - Zilate S
AD  - Department of Pharmacology, Jawaharlal Nehru Medical College, Datta Meghe 
      Institute of Medical Sciences, Wardha, IND.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221020
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9674197
OTO - NOTNLM
OT  - autoimmune disorders
OT  - hormone replacement therapy (hrt)
OT  - infertility
OT  - premature ovarian failure (pof)
OT  - stem cell transplantation
OT  - umbilical cord-derived mesenchymal stem cells (ucmsc)
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/11/24 06:00
MHDA- 2022/11/24 06:01
PMCR- 2022/10/20
CRDT- 2022/11/23 02:06
PHST- 2022/09/14 00:00 [received]
PHST- 2022/10/20 00:00 [accepted]
PHST- 2022/11/23 02:06 [entrez]
PHST- 2022/11/24 06:00 [pubmed]
PHST- 2022/11/24 06:01 [medline]
PHST- 2022/10/20 00:00 [pmc-release]
AID - 10.7759/cureus.30529 [doi]
PST - epublish
SO  - Cureus. 2022 Oct 20;14(10):e30529. doi: 10.7759/cureus.30529. eCollection 2022 
      Oct.